Neumora Therapeutics (NMRA) Equity Ratio (2022 - 2026)

Neumora Therapeutics has reported Equity Ratio for 5 years, with the latest figure at 0.46 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 48.36% year-over-year to 0.46; the trailing twelve-month figure through Mar 2026 stood at 0.46 (down 48.36% YoY), and the FY2025 full-year result was 0.54, down 39.97% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.46, down from 0.54 in the prior quarter.
• The five-year high for Equity Ratio was 0.95 in Q4 2023, with the low at 1.05 in Q4 2022.
• Average Equity Ratio over 5 years is 0.67, with a median of 0.9 recorded in 2025.
• Year-over-year, Equity Ratio soared 190.17% in 2023 and tumbled 48.36% in 2026.
• Tracing NMRA's Equity Ratio over 5 years: stood at 1.05 in 2022, then soared by 190.17% to 0.95 in 2023, then retreated by 4.2% to 0.91 in 2024, then sank by 39.97% to 0.54 in 2025, then retreated by 15.52% to 0.46 in 2026.
• The last three Equity Ratio figures came in at 0.46 (Q1 2026), 0.54 (Q4 2025), and 0.74 (Q3 2025), per Business Quant data.

Peer Comparison